Goldman Sachs
AGRX

Goldman Sachs’s Agile Therapeutics AGRX Stock Holding History

Goldman Sachs’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12
Closed -$12K – 7069
2021
Q4 		$12K Buy
+12
New +$16.9K ﹤0.01% 6407
2021
Q3 		– Sell
-114
Closed -$305K – 6618
2021
Q2 		$305K Buy
114
+97
+571% +$320K ﹤0.01% 5513
2021
Q1 		$73K Buy
17
+8
+89% +$43.2K ﹤0.01% 5895
2020
Q4 		$50K Sell
9
-1
-10% -$5.89K ﹤0.01% 5385
2020
Q3 		$62K Buy
+10
New +$57.3K ﹤0.01% 5157
2020
Q2 		– Sell
-32
Closed -$118K – 5559
2020
Q1 		$118K Buy
+32
New +$184K ﹤0.01% 4904
2018
Q2 		– Sell
-7
Closed -$34K – 6125
2018
Q1 		$34K Sell
7
-1
-13% -$6.61K ﹤0.01% 5577
2017
Q4 		$41K Buy
+8
New +$74.5K ﹤0.01% 5983
2017
Q3 		– Sell
-41
Closed -$309K – 6935
2017
Q2 		$309K Buy
+41
New +$284K ﹤0.01% 5483
2015
Q3 		– Sell
-24
Closed -$405K – 7546
2015
Q2 		$405K Sell
24
-8
-25% -$171K ﹤0.01% 5419
2015
Q1 		$597K Buy
32
+4
+14% +$70.1K ﹤0.01% 4956
2014
Q4 		$348K Sell
28
-14
-33% -$178K ﹤0.01% 5629
2014
Q3 		$612K Buy
42
+31
+282% +$479K ﹤0.01% 5089
2014
Q2 		$194K Buy
+11
New +$159K ﹤0.01% 6222

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's AGRX Position: Q1 2022 in Review

Goldman Sachs sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 12 shares — an estimated $12K sold.

Goldman Sachs first reported a position in AGRX in Q2 2014 and held it in 14 quarters. The position peaked at $612K in Q3 2014. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

  • Goldman Sachs reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 12 Agile Therapeutics shares in Q1 2022, an estimated $12K.
  • Goldman Sachs first reported a position in Agile Therapeutics in Q2 2014 and held it in 14 quarters.
  • Goldman Sachs's Agile Therapeutics position peaked at $612K in Q3 2014.
  • 36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.